• Hub Login
  • Contact
  • Investors
  • Viveve Solutions
    • Viveve System
    • InControl by Viveve
  • Clinical Studies
  • About
    • Mission
    • Leadership
    • Careers
  • News
    • Blog
    • Media & Press
    • Investor News
    • Events
  • Testimonials
Select Page
Dev Site

A Global Women’s Intimate Health Company

Press Releases

Investors
  • Overview
  • News / Events
    • Overview
    • Press Releases
    • Publications
    • IR Calendar
    • Analyst Coverage
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Clinical Advisory Board
    • Medical Consultants
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Investor Presentation
    • Contacts
    • RSS News Feed
  • News / Events

  • Overview
  • Press Releases
  • Publications
  • IR Calendar
  • Analyst Coverage
  • Email Alerts

Viveve to Present at Stifel 2018 Healthcare Conference

Nov 8, 2018

Viveve Reports Third Quarter 2018 Financial Results

Nov 8, 2018

Viveve to Host Conference Call to Discuss Third Quarter 2018 Financial and Operating Results

Nov 1, 2018

Viveve to Present at Ladenburg Thalmann 2018 Healthcare Conference

Sep 25, 2018

Viveve Appoints Two New Independent Board Members

Sep 13, 2018

Viveve Submits Investigational Device Exemption to FDA to Conduct LIBERATE-U.S. Trial for Improvement of Stress Urinary Incontinence

Sep 11, 2018

Viveve to Present at 20th Annual Rodman & Renshaw Global Investment Conference

Aug 28, 2018

Viveve Initiates LIBERATE-International Trial for Improvement of Stress Urinary Incontinence

Aug 14, 2018

Viveve Reports Second Quarter 2018 Financial Results and Provides Corporate Update

Aug 9, 2018

Viveve Announces FDA Approval to Continue VIVEVE II Clinical Study

Aug 7, 2018
RSS
    • 1...
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • ...30

    Solutions

    • Viveve System
    • InControl Products
    • Common Conditions

    About

    • Mission
    • Leadership
    • Contact Us
    • Investor Information

    News

    • Viveve Blog
    • Events
    • News & Publications
    • Testimonials

    Resources

    • Hub Login
    • Careers with Viveve
    • Support Center
    Dev Site
    345 Inverness Drive South • Building B, Suite 250 • Englewood, CO 80112
    The Viveve® System is an internationally patented cryogen-cooled, monopolar radiofrequency (CMRF) energy-based device. It has received regulatory approvals and clearances in many countries throughout the world and is available through physician import license in Japan. Country-specific approved indications include: • In Argentina the Viveve System is indicated for the treatment of urinary incontinence, vaginal laxity, and sexual function. • In Australia, Brazil, Canada, Chile, Colombia, Costa Rica, Dominican Republic, Hong Kong, Japan, Mexico, Panama, Philippines, Singapore, Uruguay, and Venezuela the Viveve System is indicated for the treatment of the vaginal introitus, after vaginal childbirth, to improve sexual function. • In the EU, Bahrain, Iceland, Korea, Kuwait, Lebanon, Liechtenstein, Norway, South Africa, Switzerland, and Ukraine the Viveve System is indicated for the treatment of vaginal laxity. • In Peru, Taiwan, and the United States the Viveve System is cleared for general surgical procedures for electrocoagulation and hemostasis.